Warfarin pharmacogenetics in patients with heart valve replacement


Bezci K., Cevik M., Akdeniz C. S. , Canbolat I. P. , Yurdakul S., SÜNBÜL M. , ...More

GENE REPORTS, vol.20, 2020 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 20
  • Publication Date: 2020
  • Doi Number: 10.1016/j.genrep.2020.100769
  • Title of Journal : GENE REPORTS
  • Keywords: Warfarin, CYP2C9, Heart valve replacement, Polymorphism, REDUCTASE COMPLEX SUBUNIT-1, VITAMIN-K ANTAGONISTS, BLEEDING COMPLICATIONS, GENE POLYMORPHISMS, ANTICOAGULANT-THERAPY, CYP2C9 POLYMORPHISM, ATRIAL-FIBRILLATION, VKORC1, ASSOCIATION, VARIABILITY

Abstract

Background: Warfarin treatment is crucial to prevent thrombolytic complications after the heart valve replacement (HVR) operation. Our purpose was to investigate the prevalence of CYP2C9 *2 and *3 gene polymorphisms, which are essential in warfarin metabolism in patients with and without HVR surgery prescribed with warfarin.